The need for a low-risk OHSS protocol necessitated the implementation of GnRH antagonist protocols, which subsequently paved the way for the introduction of a GnRH agonist for triggering oocyte maturation (Humaidan et al., 2011). This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.